PeptidePedia The community reference

Temperature excursion (revision 8)

Old revision·15:27, 1 May 2025·CrudePeptidePearl

This is an old revision of this page, as it stood at 15:27, 1 May 2025, saved by CrudePeptidePearl with the summary split overlong sentence. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Temperature excursion
DefinitionDeviation outside labelled storage conditions
Assessed byDuration, magnitude and cumulative exposure
Summary statisticMean kinetic temperature
Disposition outcomesRelease, shortened dating, or rejection
Topic infobox · conventions

A temperature excursion is an episode in which a product is held outside the storage conditions stated on its label. The term is used in pharmaceutical distribution and manufacturing for a deviation whose consequences must be assessed before the product is released for further use, and the assessment is a documented judgement about degradation rather than a rule about temperature.[1]

An excursion is defined relative to a label, not to an absolute temperature. Because compendial definitions of controlled cold and controlled room temperature build permitted excursion bands into the definitions themselves, a departure from the nominal range is not automatically an excursion in the regulatory sense; a product labelled for storage at 2–8 °C that reaches 15 °C for an hour may remain within its labelled conditions, whereas the same profile applied to a product labelled for frozen storage would not.[2]

Assessment proceeds from three quantities: how far outside the range the product went, for how long, and how much such exposure it has already accumulated. Duration and magnitude are combined through the mean kinetic temperature, a degradation-weighted average that gives disproportionate weight to warm intervals and can exceed the permitted range even when the ordinary time-weighted mean does not. Cumulative accounting matters because a product that has spent three separate periods outside its range has consumed three portions of whatever stability margin the manufacturer's programme established.[3][1]

Definition and framing

[edit]

Distribution and compendial guidance treat an excursion as a deviation requiring investigation. The European good distribution practice guidelines require that deviations be recorded and their effect on quality evaluated, and that product not be released for further distribution until that evaluation is complete. WHO model guidance takes the same approach and adds the concept of a stability budget: the total permitted exposure outside labelled conditions, allocated across the product's life, against which each event is charged.[4][5]

Three framings of the same event coexist and are worth distinguishing.

The compliance framing
Did the product leave its labelled conditions? This is answered by comparing a record against a label, and is a question about documents.
The kinetic framing
How much additional degradation is expected? This is answered by applying a rate model to the exposure, and is a question about chemistry.
The analytical framing
Can any change be measured? This is answered by testing, and is a question about method capability.

The three can disagree, and the disagreement is informative rather than paradoxical. A brief excursion may be a compliance failure while producing degradation far below the detection limit of any available assay; conversely a profile within the permitted band may still cause measurable change in a product whose stability is marginal. Assessment practice therefore uses all three: compliance to determine whether an investigation is required, kinetics to predict, and testing to confirm.[1][6]

References

  1. ^ a b c United States Pharmacopeia, General Chapter <1079>, "Risks and Mitigation Strategies for the Storage and Transportation of Finished Drug Products" (informational). USP–NF, current revision.
  2. ^ United States Pharmacopeia, General Chapter <659>, "Packaging and Storage Requirements". USP–NF, current revision.
  3. ^ Haynes JD. "Worldwide virtual temperatures for product stability testing." Journal of Pharmaceutical Sciences 60(6):927–929 (1971).
  4. ^ European Commission. Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (2013/C 343/01).
  5. ^ World Health Organization. "Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products." WHO Technical Report Series No. 961, Annex 9 (2011).
  6. ^ Waterman KC, Adami RC. "Accelerated aging: prediction of chemical stability of pharmaceuticals." International Journal of Pharmaceutics 293(1–2):101–125 (2005).